GlucoScreen

Author:

Waghmare Anandghan1ORCID,Parizi Farshid Salemi2ORCID,Hoffman Jason1ORCID,Wang Yuntao1ORCID,Thompson Matthew3ORCID,Patel Shwetak1ORCID

Affiliation:

1. Paul G. Allen School for Computer Science & Engineering, University of Washington

2. Department of Electrical & Computer Engineering, University of Washington

3. Department of Family Medicine, University of Washington

Abstract

Blood glucose measurement is commonly used to screen for and monitor diabetes, a chronic condition characterized by the inability to effectively modulate blood glucose that can lead to heart disease, vision loss, and kidney failure. Early detection of prediabetes can forestall or reverse more serious illness if healthy lifestyle adjustments or medical interventions are made in a timely manner. Current diabetes screening methods require visits to a healthcare facility and use of over-the-counter glucose-testing devices (glucometers), both of which are costly or inaccessible for many populations, reducing the chances of early disease detection. We therefore developed GlucoScreen, a readerless glucose test strip that enables affordable, single-use, at-home glucose testing, leveraging the user's touchscreen cellphone for reading and displaying results. By integrating minimal, low-cost electronics with commercially available blood glucose testing strips, the GlucoScreen prototype introduces a new type of low-cost, battery-free glucose testing tool that works with any smartphone, obviating the need to purchase a separate dedicated reader. Our key innovation is using the phone's capacitive touchscreen for the readout of the minimally modified commercially available glucose test strips. In an in vitro evaluation with artificial glucose solutions, we tested GlucoScreen with five different phones and compared the findings to two common glucometers, AccuChek and True Metrix. The mean absolute error (MAE) for our GlucoScreen prototype was 4.52 mg/dl (Accu-Chek test strips) and 3.7 mg/dl (True Metrix test strips), compared to 4.98 mg/dl and 5.44 mg/dl for the AccuChek glucometer and True Metrix glucometer, respectively. In a clinical investigation with 75 patients, GlucoScreen had a MAE of 10.47 mg/dl, while the AccuChek glucometer had a 9.88 mg/dl MAE. These results indicate that GlucoScreen's performance is comparable to that of commonly available over-the-counter blood glucose testing devices. With further development and validation, GlucoScreen has the potential to facilitate large-scale and lower cost diabetes screening. This work employs GlucoScreen's smartphone-based technology for glucose testing, but it could be extended to build other readerless electrochemical assays in the future.

Publisher

Association for Computing Machinery (ACM)

Subject

Computer Networks and Communications,Hardware and Architecture,Human-Computer Interaction

Reference96 articles.

1. 2007. Los Angeles Times. https://www.latimes.com/archives/la-xpm-2007-nov-07-fi-lazarus7-story.html. [Online accessed 12-April-2022]. 2007. Los Angeles Times. https://www.latimes.com/archives/la-xpm-2007-nov-07-fi-lazarus7-story.html. [Online accessed 12-April-2022].

2. Glucose oxidase --- An overview;Biotechnology Advances,2009

3. 2015. Screening for Abnormal Blood Glucose and Type 2 Diabetes Mellitus: U.S. Preventive Services Task Force Recommendation Statement. Annals of Internal Medicine 163, 11 ( 2015 ), 861--868. https://doi.org/10.7326/M15-2345 arXiv:https://doi.org/10.7326/M15-2345 PMID : 26501513. 10.7326/M15-2345 2015. Screening for Abnormal Blood Glucose and Type 2 Diabetes Mellitus: U.S. Preventive Services Task Force Recommendation Statement. Annals of Internal Medicine 163, 11 (2015), 861--868. https://doi.org/10.7326/M15-2345 arXiv:https://doi.org/10.7326/M15-2345 PMID: 26501513.

4. 2017. Clinical Diabetes/Therapeutics. https://doi.org/10.2337/db17-890-1488. [Online accessed 13-February-2022]. 10.2337/db17-890-1488 2017. Clinical Diabetes/Therapeutics. https://doi.org/10.2337/db17-890-1488. [Online accessed 13-February-2022].

5. 2019. Frequently Asked Questions regarding Control Solution Testing. https://www.trividiahealth.com/wp-content/uploads/2019/03/Control_Solution_FAQ.pdf/. [Online accessed 13-February-2022]. 2019. Frequently Asked Questions regarding Control Solution Testing. https://www.trividiahealth.com/wp-content/uploads/2019/03/Control_Solution_FAQ.pdf/. [Online accessed 13-February-2022].

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3